Orticumab Drug Asset Due Diligence Report 2026

This Orticumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Orticumab can convert its Monoclonal antibody profile and Low-density lipoprotein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Orticumab (query alias: Orticumab)
Modality / target	Monoclonal antibody; Low-density lipoprotein; Low-density lipoprotein modulators
Highest global status	Phase 2
Originator	BioInvent International AB
Active developers	Abcentra LLC

The MCP disease footprint includes Acute Coronary Syndrome, Non-St Elevated Myocardial Infarction, ST Elevation Myocardial Infarction. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06927739	Phase 2	Recruiting	240	Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeks
NCT01258907	Phase 2	Completed	147	Change in TBR as measured by FDG-PET/CT
NCT04776629	Phase 2	Completed	77	Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

Phase 2; n=77; evaluation: not stated. Reported fields: Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)(Mean) = -18.95 Percentage change of score (Standard Deviation, 25.165); Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)(Mean) = -25.45 Percentage change of score (Standard Deviation, 26.552); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Orticumab addresses Acute Coronary Syndrome, Non-St Elevated Myocardial Infarction, ST Elevation Myocardial Infarction. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-06-21	Green-Life Technology 与 Abcentra LLC订立许可及合作协议，获得Orticumab的商业化授权许可	Phase 2	US$2.0M upfront; US$22.0M milestones
2018-09-27	BioInvent signs licensing and manufacturing agreement with CardioVax for the development of orticumab	Preclinical	US$3.0M stated total
2007-01-12	BioInvent Enters Collaboration With Genentech	Preclinical	US$15.0M upfront; US$175.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of identifying a subject for treatment with antibodies against oxidized low density lipoprotein using pericoronary fat attenuation index”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO